Active, not recruitingPHASE2, PHASE3NCT04669496

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Zhongshan Hospital
Principal Investigator
Jia Fan, MD & PhD
Shanghai Zhongshan Hospital
Intervention
Neoadjuvant treatment(drug)
Enrollment
178 target
Eligibility
18-70 years · All sexes
Timeline
2021 – 2026

Study locations (1)

Collaborators

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai Public Health Clinical Center · RenJi Hospital · Shenzhen University General Hospital · Sir Run Run Shaw Hospital · Tang-Du Hospital · First Affiliated Hospital of Wenzhou Medical University · The First Affiliated Hospital of Zhengzhou University · The First Affiliated Hospital of Anhui Medical University · First Hospital of China Medical University · Eastern Hepatobiliary Surgery Hospital · First Affiliated Hospital Xi'an Jiaotong University · Shanghai Jiao Tong University Affiliated Sixth People's Hospital · First Affiliated Hospital of Guangxi Medical University · The Affiliated Hospital of Qingdao University · Peking Union Medical College Hospital · Meng Chao Hepatobiliary Hospital of Fujian Medical University · The First Affiliated Hospital of University of Science and Technology of China · Cancer Hospital of Guangxi Medical University · Tongji Hospital · Zhejiang Provincial People's Hospital · The Second Affiliated Hospital of Kunming Medical University · Sichuan Provincial People's Hospital · Taizhou Hospital · Shaoxing People's Hospital · The First Hospital of Hebei Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04669496 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials